Development of Glucose-Responsive Insulin
Technical Report,01 Mar 2019,29 Feb 2020
University of Utah Salt Lake City United States
Pagination or Media Count:
One therapeutic limitation of current insulin therapy in people with diabetes is that there is no control of insulin action once insulin is injected. That is, currently available injected insulin analogs can cause severe hypoglycemia if overdosed and remain biologically active, even when blood sugars are falling into dangerously low levels. Thus, hypoglycemia is the rate-limiting step in the glycemic management of diabetes due to the narrow therapeutic window of current insulin therapies. To reduce the risk of hypoglycemia, a glucose-responsive insulin GRI derivative is what is active when blood glucose levels are high, yet is inactivated when blood glucose levels start to decline is proposed in this work. Such a smart insulin will eliminate the barrier of hypoglycemia for insulin-treated people with diabetes. To achieve this goal, it is proposed to develop new glucose-responsive insulin therapies such that the risk of hypoglycemia can be minimized.
- Medicine and Medical Research